Biogen: Alzheimer's Disease Treatment Needs More Real-World Data (NASDAQ:BIIB)

Core Insights - Eisai's Leqembi has been highlighted for its potential to slow the progression of Alzheimer's disease, despite the CTAD conference yielding no major breakthroughs in treatment [1] Group 1: Alzheimer's Disease Research - The article emphasizes that Alzheimer's disease is primarily caused by oxidation and nitration, with many current treatments only addressing symptoms rather than the root causes [1] - Most Alzheimer's treatments focus on misfolded amyloid and tau proteins and neuroinflammation, but few target oxidative and nitrostative stress directly [1] - Natural products like panax ginseng and essential oils are suggested to have the potential to stabilize Alzheimer's disease by inhibiting oxidation and nitration [1]